NeoImmuneTech

Neo Immune Tech

Biotechnology, 2400 Research Blvd., Rockville, Maryland, 20850, United States, 11-50 Employees

neoimmunetech.com

  • twitter
  • LinkedIn

Who is NEOIMMUNETECH

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases....

Read More

map
  • 2400 Research Blvd., Rockville, Maryland, 20850, United States Headquarters: 2400 Research Blvd., Rockville, Maryland, 20850, United States
  • 2014 Date Founded: 2014
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from NEOIMMUNETECH

NeoImmuneTech Org Chart and Mapping

Employees

Tolani Adebanjo

Clinical Project Manager

Jennifer Gallagher

Head of Transactions and Alliance Management

Sungkyun Ahn

Senior Accounting Manager

Abdulshakur Abdullah

Senior Business Development Manager

Hyesun Kim

Human Resources Business Partner

Helena Holsey

Clinical Trial Specialist

Lauren Gorelik

Clinical Project Manager

Sun Hwang

Human Resources Generalist

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding NeoImmuneTech

Answer: NeoImmuneTech's headquarters are located at 2400 Research Blvd., Rockville, Maryland, 20850, United States

Answer: NeoImmuneTech's official website is https://neoimmunetech.com

Answer: NeoImmuneTech's revenue is $5 Million to $10 Million

Answer: NeoImmuneTech's SIC: 2836

Answer: NeoImmuneTech's NAICS: 541714

Answer: NeoImmuneTech has 11-50 employees

Answer: NeoImmuneTech is in Biotechnology

Answer: NeoImmuneTech contact info: Phone number: Website: https://neoimmunetech.com

Answer: NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access